

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Lorna W. Role, et al.

Serial No. : 09/312,596

Filing Date : May 14, 1999

For  A-FORM OF CYTOPLASMIC DOMAIN OF nARIA (CRD-NEUREGULIN) AND USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
November 1, 2000


Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) and submitted in connection with the above-identified application, has the same content as that submitted herewith as **Exhibit D** entitled "Sequence Listing."

Respectfully submitted,



Jane M. Love, Ph.D.
Registration No. 42,812
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

WD GAU 1646

Box SEQ

Dkt 59360/JPW/JML

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Lorna W. Role et al.

Serial No. : 09/312,596

Examiner: M. Pak

Filed

May 14, 1999

Art Unit: 1646

For



A-FORM OF CYTOPLASMIC DOMAIN OF nARIA (CRD-NEUREGULIN) AND USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
November 1, 2000

RECEIVED

NOV 07 2000

TECH CENTER 1600/2000

7/B
D.83
11/15/00

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

NOV 09 2000

TECH CENTER 1600/2000

Sir:

COMMUNICATION IN REPLY TO OCTOBER 3, 2000 COMMUNICATION
AND NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

This Communication is submitted in response to the October 3, 2000 Communication issued by the U.S. Patent and Trademark Office in connection with the above-identified application. Applicants attach hereto a copy of the October 3, 2000 Notice to Comply with Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures as **Exhibit A**. A response to the October 3, 2000 Communication is due November 3, 2000. Accordingly, this Communication is being timely filed.

Sequence Listing

The Examiner stated that the application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. §1.821(a)(1) and (a)(2), and that the application fails to comply with these requirements.

Lorna W. Role et al.
U.S. Serial No.: 09/312,596
Filed: May 14, 1999
Page 2

RECEIVED
NOV 09 2000
TECH CENTER 1600/2300

In reply, applicants submit herewith a paper copy of a Sequence Listing as **Exhibit B**. Applicants also enclose a computer readable copy of the Sequence Listing on the enclosed computer diskette, which has the same content as the paper copy attached as **Exhibit B**. Finally, applicants submit herewith as **Exhibit C**, a Statement In Accordance With 37 C.F.R. §1.821(f) averring that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) and submitted in connection with the above-identified application, has the same information as that contained in the paper copy of the Sequence Listing attached hereto as **Exhibit B**.

Accordingly, applicants believe that the application now complies with the requirements under 37 C.F.R. §1.821(a)(1) and (a)(2).

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone at the number provided below.

Lorna W. Role et al.
U.S. Serial No.:09/312,596
Filed: May 14, 1999
Page 3

RECEIVED
NOV 09 2000
TECH CENTER 1600/2900

No fee, is deemed necessary in connection with the filing of this Communication. However, if any additional fee is required, authorization is given to charge the amount of any such fee to Deposit Account No. 03-3125.


Respectfully submitted,

Jane M. Love

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231.

Jane M. Love 11/1/00
Date
John P. White
Reg. No. 28,678
Jane M. Love
Reg. No. 42,812

John P. White
Registration No. 28,678
Jane M. Love
Registration No. 42,812
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400



Application No.: 09/312,596

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

RECEIVED

NOV 09 2000

TECH CENTER 1600-2900

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE